<DOC>
	<DOCNO>NCT01803074</DOCNO>
	<brief_summary>The primary purpose study study safety tolerability HIV drug evaluate decrease HIV-1 virus level blood treatment HIV-1 infect patient</brief_summary>
	<brief_title>Study Evaluate HIV Drug Treatment HIV Infection</brief_title>
	<detailed_description>Masking : Open-Part B . Double Blind-Parts A C Gender : Both female male participant Parts A C. Male participant Part B. HIV = Human Immunodeficiency Virus RNA = Ribonucleic acid</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Age 1855 year inclusive Men woman : ( Parts A C ) ; men ( Part B ) Women childbearing potential ( WOCBP ) must pregnant nursing BMI : 18.035.0 kg/m2 Subjects infect HIV1 ( clade B C ) meet follow criterion screen : ) Plasma HIV1 RNA ≥5,000 copies/mL ; ii ) Antiretroviral treatment naive ( define &lt; 1 week ARV treatment ) ARTexperienced ( protease inhibitor and/or maturation inhibitor naive ) ; iii ) Subjects eligible HIV1 treatment base United States Department Health Human Services Panel Antiretroviral Guidelines Adults Adolescents decline initiation cART iv ) CD4+ lymphocyte measurement ≥200 cells/μL ; v ) In Parts A B , subject infected HIV1 clade B vi ) In Part C , subject infected HIV1 clade C History genotypic and/or phenotypic drug resistance test show resistance protease inhibitor Any significant acute chronic medical illness stable control medication consistent HIV1 infection Receive antiretroviral treatment within 12 week prior screen Currently coinfected hepatitis C hepatitis B Previously receive HIV maturation inhibitor HIV protease inhibitor Current recent ( within 3 month study drug administration ) gastrointestinal disease Any major surgery within 4 week study drug administration Acute diarrhea lasting ≥1 day , within 3 week prior randomization Subjects history Gilbert 's syndrome Subjects previously receive HIV maturation inhibitor HIV protease inhibitor A personal history clinically relevant cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor torsades de pointes . A personal family history long QT syndrome Patients unwilling practice adequate infection protection study participation minimize potential spread HIV infection , include HIV may develop resistance HIV maturation inhibitor and/or ATV Any gastrointestinal surgery could impact upon absorption study drug Smoking &gt; 10 cigarette per day PR ≥210 msec ; QRS ≥120 msec ; QT ≥500 msec ; QTcF ≥470 msec woman ≥450 msec men Evidence second third degree heart block prior study drug Absolute Neutrophil Count &lt; ( ANC ) 0.7 x low limit normal ( LLN ) Hemoglobin &lt; 0.8 x LLN Alanine aminotransferase ( ALT ) &gt; 1.25 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; 1.25 x ULN Total Bilirubin &gt; 1.25 x ULN Creatinine clearance &lt; 60 mL/mim Positive urine screen drug abuse without valid prescription ( subject positive cannabinoids and/or amphetamine include ) Positive blood screen hepatitis C virus ( HCV ) RNA , hepatitis B surface antigen ( consistent active chronic hepatitis B ) , HIV2 antibody History significant drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>